anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a randomised, double blind, placebo-controlled, two-way cross-over study to evaluate the effect of treatment with repeat dose GSK2190915, a 5-lipoxygenase-activating protein (FLAP) inhibitor, as an add-on to current therapy on the percentage of neutrophils in induced sputum in asthmatic patients with elevated sputum neutrophils. Approximately 20 subjects will be enrolled onto the study to ensure that approximately 14 evaluable subjects complete the study. All subjects will receive oral placebo and GSK2190915 100mg once daily for up to 16 days. Sputum neutrophilia will be assessed prior to treatment and on treatment. Key assessments: sputum cell counts, biomarker samples in sputum, blood and urine, and pharmacokinetics. Safety will be assessed by vital signs, electrocardiograms (ECGs), clinical laboratory safety tests and collection of adverse events (AEs).

GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that attenuates the production of leukotrienes, through the blockage of the first committed step in the leukotriene pathway, 5-lipoxygenase (5-LO) activation. Leukotrienes are potent inflammatory molecules produced mainly by mast cells, eosinophils, monocytes/macrophage and neutrophils in response to allergic or inflammatory stimuli. As GSK2190915 reproducibly inhibits the production of leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs) both in vitro and in vivo it has strong potential utility in the treatment of asthma.
965,063. Kallikrein-inactivators. FARBENFABRIKEN BAYER A.G. Feb. 6, 1963 [Feb. 19, 1962], No. 4835/63. Heading A5B. The sparingly,- water-soluble reaction product of the kallikrein-inactivator with metaphosphoric acid is produced by reacting the kallikrein-inactivator in aqueous solution with metaphosphoric acid and recovering the precipitate. Alternatively, a water-soluble salt of metaphosphoric acid, e.g. the alkali metal or ammonium salt may be used, in which case the desired compound is obtained by acidification and separation of the precipitate. Crude kallikrein-inactivator may be purified by treating an aqueous solution with metaphosphoric acid, separating the precipitate, dissolving the precipitate in an aqueous solution of an alkali metal hydroxide, ammonium hydroxide or a salt thereof, and passing the solution so formed through an ion-exchange column containing a mixed anion and cation exchange resin and recovering the purified kallikreininactivator. Alternatively, the solution may be passed through an anionic exchange resin and then through a cationic exchange resin or may be dialysed to remove the inorganic salts. The kallikrein-inactivator metaphosphoric acid derivative may be injected. Specification 886,989 is referred to.
This product contains potassium and sodium and should be used with caution if regulation of these elements is desired. Occasionally, some individuals may experience a mild laxative effect during the first few days of phosphate therapy. If laxation persists to an unpleasant degree, reduce the daily dosage until this effect subsides or, if necessary, discontinue the use of this product.

Caution should be exercised when prescribing this product in the following conditions: Cardiac disease (particularly in digitalized patients); severe adrenal insufficiency (Addison's disease); acute dehydration; severe renal insufficiency; renal function impairment or chronic renal disease; extensive tissue breakdown (such as severe burns); myotonia congenita; cardiac failure; cirrhosis of the liver or severe hepatic disease; peripheral or pulmonary edema; hypernatremia; hypertension; toxemia of pregnancy; hypoparathyroidism; and acute pancreatitis. Rickets may benefit from phosphate therapy, but caution should be exercised. High serum phosphate levels may increase the incidence of extra-skeletal calcification.
Participants receive selumetinib PO BID on days 1-7 and 15-21 and durvalumab intravenously (IV) over 60 minutes on day 1. Participants also receive tremelimumab IV over 60 minutes on day 1 for courses 1-4. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention discloses a miRNA marker of acute myeloid leukemia and application thereof. Application of miRNA-146 in preparation of acute myeloid leukemia auxiliary diagnosis reagent as miRNA marker for detecting acute myeloid leukemia. Application of a primer, a probe or a gene chip for detecting miRNA-146 in preparation of an acute myeloid leukemia auxiliary diagnostic reagent. The primer for detecting miRNA-146 preferably consists of an upstream primer shown by SEQ ID NO.1 and a downstream primer shown by SEQ ID NO. 2. The invention discovers that the expression level of miRNA-146 is related to the occurrence of AML for the first time, and whether the subject suffers from AML can be judged by detecting the expression level of miRNA-146 of the subject, so that the patient can take corresponding prevention and treatment measures in the early stage of suffering from the AML.
In the rapidly changing face of surgical education and with a pressure to adopt competency-based training and assessment nationwide, obstetrics and gynecology residency programs will be forced to implement effective strategies to ensure that learners acquire the skill set required to become competent gynecologists. However, very few instructional tools have been validated in gynecologic surgery. The use of surgical videos as a teaching strategy may be one piece to this puzzle. Surgical videos are becoming increasingly popular, however, their value as an effective instructional technique has yet to be validated. Should surgical videos prove to be of benefit in surgical training it would offer an alternate modality to optimize operating room experiences and learning for gynecology residents.

Obstetrics and gynecology residents in years one and two of their training (junior residents), will view a teaching video about LSO (intervention group) compared to not watching a video (control group) to assess if our intervention results in better performance in the operating room for this procedure as rated by an objective structured assessment of technical skills tool (OSAT) (primary outcome). Secondary outcome measures will include a self-administered questionnaire grading knowledge and confidence, and a 5-point Likert scale grading resident satisfaction with the video.
As healthcare systems grow increasingly complex, greater demands are placed on patients' abilities to find, understand, appraise, and use health information - often termed their 'health literacy'. Most health literacy research does not focus on information appraisal. When it does, there is a tendency to equate it with patients' assessment of credibility. This reproduces a healthcare-centric understanding of information appraisal where patient agency is omitted. This study explores how participants in a health information intervention practiced information appraisal. The intervention aimed to increase information uptake for people with low back pain by delivering health information to them through animations. This study draws on ethnographic participant observation of the encounters between the intervention and its participants, including 49 rapid interviews and semi-structured telephone interviews with 23 participants carried out in the spring of 2021. Inspired by a social practice approach, the study thoroughly grounds the health literacy subcategory of 'appraisal' in practice. It illustrates that participants appraised the information provided in the intervention according to several factors. These include relating the information to their personal health needs, interpreting the intended audience of the health animations, and prioritising their attention situationally between the animations and other immediate concerns. We suggest that information appraisal is a fundamental component of health literacy and should be considered key in research, policy and practice. To accommodate current healthcare ideals of patient centeredness, empowerment and informed choice, the complex and dynamic ways in which people appraise health information need be considered legitimate practices of health literacy.
PURPOSE:To obtain a medicated cream, containing an extract substance of Glycyrrhizae Radix, an extract solution of Sophora angustofolia Sieb. et Zucc. and further, as necessary, an extract solution of Scutellariae Radix and effective for allergic diseases, especially for dermatitides in ducted by the contact with materials such as metals, cosmetics or Japanese lacquer. CONSTITUTION:A medicated cream containing 0.05-0.5% extract substance of Glycyrrhizae Radix consisting mainly of glycyrrhetinic acid, 1-10% extract solution of Sophora angustifolia Sieb. et Zucc. and further, as necessary, 1-10% extract solution of Scutellariae Radix. Synergistic effects are exhibited by combining respective abilities of antiinflammatory action of the extract substance from the Glycyrrhizae Radix, ulcerogenic preventive ability matrine which is a main alkaloid in the extract solution of the Sophora angustifolia Sieb. et Zucc., responding ability to skin infectious diseases antiinflammatory, antiallergic and suppressing actions on atopic type reaction of the extract solution of the Scutellariae Radix as a flavonoid, together with their individual effects.
Propofol is a hypnotic drug commonly used for induction and maintenance of general anesthesia. Propofol is adiministered intravenously and has a comfortable side effect profile. Patients recover fast after propofol anesthesia and are less likely to suffer from post-operative nausea and vomiting compared to general anesthesia with inhalational anesthetics. However, titration of propofol can be challenging and patients may suffer from over- or underdosing during propofol anesthesia. Recent work has demonstrated that propofol is exhaled during anesthesia. Monitoring of propofol concentrations in breath gas during anesthesia may help to titrate propofol anesthesia more effectively. Yet, it is unclear how propofol concentrations vary among patients. This study aims to investigate this variation in a cohort of patients undergoing general anesthesia for elective surgical procedures. Propofol will be measured in breath gas continuously from the induction of anesthesia until recovery. Blood samples will be drawn from the start of anesthesia up to 24 h after the end of the anesthesia procedure and assayed for propofol blood concentrations. We will built a pharmacokinetic model from breath and blood measurements in order to describe the variability of propofol breath concentrations among study participants.
The accumulation of amyloid-β (Aβ) and hyperphosphorylated-tau (hp-tau) are two classical histopathological biomarkers in Alzheimer's disease (AD). However, their detailed interactions with the electrophysiological changes at the meso- and macroscale are not yet fully understood. We developed a mechanistic multiscale model of AD progression, linking proteinopathy to its effects on neural activity and vice-versa. We integrated a heterodimer model of prion-like protein propagation and a brain network model of Jansen-Rit neural masses derived from human neuroimaging data whose parameters varied due to neurotoxicity. Results showed that changes in inhibition guided the electrophysiological alterations found in AD, and these changes were mainly attributed to Aβ effects. Additionally, we found a causal disconnection between cellular hyperactivity and interregional hypersynchrony contrary to previous beliefs. Finally, we demonstrated that early Aβ and hp-tau depositions' location determine the spatiotemporal profile of the proteinopathy. The presented model combines the molecular effects of both Aβ and hp-tau together with a mechanistic protein propagation model and network effects within a closed-loop model. This holds the potential to enlighten the interplay between AD mechanisms on various scales, aiming to develop and test novel hypotheses on the contribution of different AD-related variables to the disease evolution.
Due to the actual pandemic of COVID-19 around the world, social distancing is recommended, which causes a reduction of social interaction and physical activity. Therefore, this health crisis may have collateral effects on cognitive, physical, and psychological health, especially in elderly people who are more likely to be isolated, and for whom social distancing is of paramount importance. Physical exercise practice has been demonstrated to improve cognitive functioning, along with mobility and physical capacity, and to promote psychological well-being. This is the reason why governmental health authorities, as well as the scientific community recommend to stay physically active, especially in this pandemic period. However, in the current context full-time physical training in sport centres cannot be largely promoted. Effective solutions to help older adults in maintaining regular and efficient physical exercise while maintaining social distancing, are thus needed. Consequently, the current project proposes first to investigate the potential of a remote monitoring of physical activity to promote cognitive, physical and psychological health of older adults. Also, considering the added benefits of combining cognitive training to physical exercise to further enhance health and cognition in seniors, this project also addresses the added benefits of a multidomain intervention combining a physical exercise intervention with a home-based cognitive training.
OBJECTIVE: Sepsis is considered a major cause of health loss in children and had high mortality and morbidity. Currently, there is no reliable model for predicting the prognosis of pediatric patients with sepsis. This study aimed to analyze the clinical characteristics of sepsis in children and assess the risk factors associated with poor prognosis in pediatric sepsis patients to identify timely interventions and improve their outcomes.
METHODS: This study analyzed the clinical indicators and laboratory results of septic patients hospitalized in the Pediatric Intensive Care Unit of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China, from January 1, 2019, to December 31, 2021. Risk factors for sepsis were identified by logistic regression analyses.
RESULTS: A total of 355 children with sepsis were enrolled, with 333 children (93.8%) in the good prognosis group, and 22 children (6.2%) in the poor prognosis group. Among them, there were 255 patients (71.8%) in the sepsis group, and 100 patients (28.2%) in the severe sepsis group. The length of hospital stay in the poor prognosis group was longer than that in the good prognosis group (P<0.01). The levels of interleukin 1β (IL-1β) in the poor prognosis group were higher than those in the good prognosis group (P>0.05), and the platelet (PLT), albumin (ALB), and hemoglobin (Hb) levels were lower in the poor prognosis group (P<0.01). The IL-8 levels in the severe sepsis group were higher than those in the sepsis group (P<0.05). Multiple logistic regression analysis suggested that lower Hb levels, ALB levels, peak PLT counts, and higher IL-1β levels were independent risk factors for poor prognosis in children with sepsis.
CONCLUSION: Lower Hb, ALB, and PLT counts and elevated IL-1β are independent risk factors for poor prognosis in children with sepsis.
The study will first enroll and treat six patients with MSCs for safety run in. If no more than 2 treatment-related severe adverse events (tSAEs) are observed, the study will enroll and randomize additional patients in a ratio of 1:1 to receive either MSCs or routine/supportive care.
This randomized controlled experimental study will be conducted to evaluate the effect of progressive relaxation exercise and music recital before going to sleep on sleep, quality of life and emotional state in children with epilepsy. The study will be conducted with children aged 9-16 years and their mothers hospitalized in a tertiary care hospital. Children in the progressive relaxation exercise (n=15), music recital (n=15) and control (n=15) groups will be selected similarly in terms of age, gender, educational status, duration of diagnosis and number. The data of the study will be collected with the Quality of Life Scale in Children Parent Form (QoLQS-PPP), Pediatric Symptom Checklist-17 (PSCL-17), Child Sleep Habits Questionnaire (CSHQ) to be administered to mothers and the Quality of Life Scale in Children Child and Adolescent Form (QoLQ-C), Me and My Emotions in Children and Adolescents Scale (MEAS), and Sleep Deprivation Scale for Children and Adolescents (PSSAD) to be administered to children. Children in the PRE group will be asked to do PRE before going to sleep five days a week (4 weeks) with a PRE video for a total of 15 minutes each session. Children in the music group will be asked to listen to the selected music before going to sleep five days a week (4 weeks) for a total of 15 minutes each session. These scales will be applied to the children before the interventions (Time 1). After the interventions were performed five days a week (4 weeks) for a total of 15 minutes each session before going to sleep, the same scales will be applied again (Time 2) and the results of the study will be compared. Children in the control group will receive standard treatment. In the evaluation of the data showing normal distribution; Student t (between 2 groups) and One Way ANOVA (more than 2 groups) tests will be used to test whether there is a difference between two independent groups; Paired-samples t test will be used to test whether there is a difference between the measurements before and after the intervention. In the evaluation of non-normally distributed data; Mann-Whitney U (between 2 groups) and Kruskal-Wallis Analysis of Variance (more than 2 groups) tests will be used to test whether there is a difference between two independent groups; Wilcoxon Paired-Samples Test will be used to test whether there is a difference between pre and post intervention measurements. A value of p\<0.05 was considered statistically significant in data analysis.
Obstructive sleep apnea syndrome (OSAS) and obesity go hand in hand in the majority of patients and both are associated with a systemic inflammation, immune disturbance and comorbidities such as cardiovascular disease. However, the unambiguous impact of OSAS and obesity on the individual inflammatory microenvironment and the immunological consequences of human monocytes has not been distinguished yet. Therefore, aim of this study was to investigate the impact of OSAS and obesity related factors on the inflammatory microenvironment by performing flow cytometric whole blood measurements of CD14/CD16 monocyte subsets in normal weight OSAS patients, patients with obesity but without OSAS, and patients with OSAS and obesity, compared to healthy donors. Moreover, explicitly OSAS and obesity related plasma levels of inflammatory mediators adiponectin, leptin, lipocalin and metalloproteinase-9 were determined and the influence of different OSAS and obesity related factors on cytokine secretion and expression of different adhesion molecules by THP-1 monocytes was analysed. Our data revealed a significant redistribution of circulating classical and intermediate monocytes in all three patient cohorts, but differential effects in terms of monocytic adhesion molecules CD11a, CD11b, CD11c, CX3CR1, CD29, CD49d, and plasma cytokine levels. These data were reflected by differential effects of OSAS and obesity related factors leptin, TNFα and hypoxia on THP-1 cytokine secretion patterns and expression of adhesion molecules CD11b and CD49d. In summary, our data revealed differential effects of OSAS and obesity, which underlines the need for a customized therapeutic regimen with respect to the individual weighting of these overlapping diseases.
PURPOSE: A pharmaceutical composition for anti-cancer including Jeju traditional tangerine extract as an active ingredient is provided to be able to be usefully used as a pharmaceutical composition for prevention and treatment of cancer or food for prevention and alleviation of cancer since the composition is obtained from natural materials and has no cytotoxicity. CONSTITUTION: A pharmaceutical composition for prevention or treatment of cancer comprises extract of Hassaku, one of Jeju traditional tangerines as an active ingredient. A pharmaceutical composition for prevention or treatment of cancer comprises extract of Dangyooza, one of Jeju traditional tangerines as an active ingredient. A pharmaceutical composition for prevention or treatment of cancer comprises extract of Lyokan, one of Jeju traditional tangerines as an active ingredient. The extract of Hassaku, Danyooza or Lyokan is the pericarp extract of Hassaku, Dangyooza or Lyokan. The skin extract of Hassaku, Dangyooza or Lyokan is the pericarp supercritical extract of Hassaku, Dangyooza or Lyokan.
PROBLEM TO BE SOLVED: To provide a poorly soluble drug containing microsphere with improved bioavailability of the poorly soluble drug, an oral formulation comprising the same, and a method of preparing the same.SOLUTION: A poorly soluble drug containing microsphere comprises a water-soluble polymer carrier and a poorly soluble drug. The poorly soluble drug is dispersed in the water-soluble polymer carrier in a non-crystalline form by spray drying a mixed solution in which the water-soluble polymer carrier and the poorly soluble drug are dissolved in a mixed solvent of water and an organic solvent. The microsphere does not comprise a surfactant. The water-soluble polymer carrier is hydroxypropyl methylcellulose. In the poorly soluble drug, the weight ratio of the organic solvent and water is 1:1 to 3:1. The spray drying is conducted at a spray temperature of 80 to 120°C, a spray speed of 3,000 to 5,000 rpm, and an injection speed of 10 to 100 ml/min, using an atomizer type spray dryer. This invention also provides an oral formulation comprising the same and a method of preparing the same. The poorly soluble drug is preferably fenofibrate.
Transcatheter pulmonary valve replacement (TPVR) is now frequently performed in patients with adult congenital heart disease. As the life expectancy of the population with adult congenital heart disease continues to improve, more patients will require pulmonary valve intervention. This study details the short-term and midterm clinical outcomes of patients aged ≥40 years who underwent TPVR. We performed an institutional retrospective cohort study that included patients aged ≥40 years who underwent TPVR (and clinical follow-up) from January 1, 2012 to January 1, 2024. Descriptive analyses, Kaplan-Meier survival analysis, and Cox proportional hazard modeling were used to determine outcomes and risk factors affecting survival. The study included 67 patients, and median age at TPVR was 48 years (43 to 57). Median hospital length of stay after TPVR was 1 day (1 to 3); periprocedural complications occurred in 5 patients, and acute kidney injury occurred in 1 patient. Median duration of follow-up was 3.5 years (0.1 to 9.7). There were 9 total deaths, and 1-, 3-, and 5-year Kaplan-Meier survival after TPVR was 95%, 91%, and 82%, respectively. Moderate or worse right ventricular dysfunction was present in 22 patients before TPVR and in 20 patients after TPVR. Inpatient status before TPVR negatively affected survival (hazard ratio 24.7, 3.3 to 186.1, p = 0.002). In conclusion, TPVR was performed in patients aged ≥40 years with favorable periprocedural and midterm follow-up outcomes including survival, but right ventricular dysfunction did not improve, and further exploration of the ideal timing of TPVR in this age group is warranted.